Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AutoCell-S2: UCB-MNC in HLHS Stage II Repair
NCT03779711Phase 2Active, not recruiting
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous umbilical cord blood-derived mononuclear cells in hypoplastic left heart syndrome (HLHS). Primary endpoints: Right Ventricular Fractional Area Change at 3 months and Right Ventricular Circumferential Strain at 3 months. Started Jun 2019; status: active, not recruiting.
02
Drugs
autologous umbilical cord blood-derived mononuclear cells
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT03779711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779711.